Effect of Dopaminergic Medication on Postural Sway in Advanced Parkinson’s Disease

Effect of Dopaminergic Medication on Postural Sway in Advanced Parkinson’s Disease

Background: The effect of dopaminergic therapy on balance in Parkinson’s disease (PD) remains unclear, including previous studies that excluded the effect of dyskinesias or other involuntary movements on postural sway. Additionally, medication’s effects may differ between fallers and non-fallers. In...

Full description

Bibliographic Details
Main Authors:	Fredy J. Revilla, Travis R Larsh, Ashutosh eMani, Andrew P. Duker, Cyndy eCox, Paul eSuccop, Maureen eGartner, Claudia eJarrin Tejada, Amit eBhattacharya
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-12-01
Series:	Frontiers in Neurology
Subjects:	Levodopa balance Parkinson’s disease instability Dyskinesia fall
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fneur.2013.00202/full

Similar Items

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
by: Eugene Huh, et al.
Published: (2019-01-01)

Predictors of levo-dopa induced dyskinesias in Parkinson's disease
by: R T Athulya, et al.
Published: (2020-01-01)

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
by: Francesco Cavallieri, et al.
Published: (2021-02-01)

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease
by: Debleena Guin, et al.
Published: (2017-09-01)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01)

PALLIDOTOMY IN PARKINSONIAN DISEASE: THE RENAISSANCE
by: Aurangzeb Kalhoro, et al.
Published: (2021-05-01)

Interrogating the aged striatum: Robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration
by: Timothy J. Collier, et al.
Published: (2015-05-01)

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

MALADAPTIVE PLASTICITY IN LEVODOPA-INDUCED DYSKINESIAS AND TARDIVE DYSKINESIAS: OLD AND NEW INSIGHTS ON THE EFFECTS OF DOPAMINE RECEPTOR PHARMACOLOGY
by: Antonio eCerasa, et al.
Published: (2014-04-01)

Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia
by: Mark M. Lin, et al.
Published: (2019-01-01)

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
by: Ana Muñoz, et al.
Published: (2020-06-01)

Rhabdomyolysis Related to Dyskinesia in Parkinson’s Disease
by: Hesna Bektaş, et al.
Published: (2014-04-01)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01)

Comparison of the clinical response of stereotactic ventrointermedial thalamotomy with anatomical and pathophysiological features of parkinson's disease
by: VI. Tsymbaliuk, et al.
Published: (2017-12-01)

The effectiveness of non-invasive brain stimulation in improving clinical signs of hyperkinetic movement disorders
by: Ignacio eObeso, et al.
Published: (2016-01-01)

Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation
by: Sakari Leino, et al.
Published: (2018-11-01)

The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias
by: Wei-Li Kuan, et al.
Published: (2007-03-01)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
by: Patel AB, et al.
Published: (2018-11-01)

Treatment of Levodopa-induced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial
by: Amir Hassan Habibi, et al.
Published: (2018-10-01)

Clinical Management of Drug Induced Dyskinesia in Parkinson's Disease: Why Current Approaches May Need to Be Changed to Optimise Quality of Life
by: Jean-Francois Daneault, et al.
Published: (2016-12-01)

The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias
by: Vishakh Iyer, et al.
Published: (2021-11-01)

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
by: Paolo Calabresi, et al.
Published: (2019-12-01)

Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease
by: A. A. Tappakhov, et al.
Published: (2020-02-01)

Berberis vulgaris alleviates Levodopa-induced dyskinesia in male mice
by: Mokarian Faezeh, et al.
Published: (2018-12-01)

Future Scenarios for Levodopa-induced Dyskinesias in Parkinson’s disease
by: Antonio eCerasa, et al.
Published: (2015-04-01)

Parkinsonian patients and poor awareness of dyskinesias.
by: Sara ePietracupa, et al.
Published: (2014-03-01)

Factors Associated With Dyskinesia in Parkinson's Disease in Mainland China
by: Xun Zhou, et al.
Published: (2019-05-01)

Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease
by: Fernando Botello-Villagrana, et al.
Published: (2021-01-01)

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia
by: Alberto Brugnoli, et al.
Published: (2016-01-01)

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia
by: Estefania Rojo-Bustamante, et al.
Published: (2018-10-01)

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats
by: A.A. Martinez, et al.
Published: (2015-02-01)

Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia
by: Tatsuya Ueno, et al.
Published: (2014-04-01)

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
by: Folke Sjöberg, et al.
Published: (2021-05-01)

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
by: Barbara Picconi, et al.
Published: (2008-02-01)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
by: Wu N, et al.
Published: (2018-07-01)

The blood–brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates—Evidence from in vivo neuroimaging studies
by: Arnar Astradsson, et al.
Published: (2009-09-01)

Untangling cortico-striatal connectivity and cross-frequency coupling in L-DOPA-induced dyskinesia
by: Jovana eBelic, et al.
Published: (2016-03-01)

Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases
by: WANG Kuan, et al.
Published: (2020-12-01)

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
by: Manuela eMellone, et al.
Published: (2015-07-01)

Effect of Deep Brain Stimulation on Levodopa-Induced Dyskinesias and Striatal Oscillatory Local Field Potentials in a Rat Model of Parkinson's Disease
by: M. Alam, et al.
Published: (2014-01-01)

Cannot write session to /tmp/vufind_sessions/sess_dv7eb0g03ch7hf8pa0fkhf1cv4